Does Dayvigo’s sleep benefit persist for six months?
SUNRISE 2 analyzed 949 treated adults with insomnia, comparing oral lemborexant 5 or 10 mg with placebo over six months.
Both doses improved self-reported sleep onset, overnight wakefulness, sleep efficiency and sleep quality versus placebo at month six. Most adverse events were mild or moderate; serious events were uncommon and no deaths occurred.
This supports sustained improvement in patient-reported insomnia outcomes during the controlled period.
What might this mean, and what would change the interpretation?
Sleep diaries were used. The following six months had active treatment only, so this is not a 12-month placebo-controlled comparison.
What would clarify this: Longer controlled follow-up and functional outcomes.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.